Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2817309 | 1.00 | SIGMAR1 (0.46) | SIGMAR1FFAR1KDM4EEPHX2MMP1 | |
| SCHEMBL13631280 | 0.88 | ALDH1A1 (0.41) | SIGMAR1KDM4EEPHX2POLB | |
| SCHEMBL13434260 | 0.88 | ALDH1A1 (0.41) | SIGMAR1KDM4EEPHX2POLB | |
| SCHEMBL13630926 | 0.88 | ALDH1A1 (0.41) | SIGMAR1KDM4EEPHX2POLB | |
| SCHEMBL12361787 | 0.88 | ALDH1A1 (0.41) | SIGMAR1KDM4EEPHX2POLB | |
| SCHEMBL13088860 | 0.81 | L3MBTL1 (0.46) | SIGMAR1FFAR1EPHX2MMP1MMP13 | |
| SCHEMBL2816591 | 0.81 | L3MBTL1 (0.46) | SIGMAR1FFAR1EPHX2MMP1MMP13 | |
| SCHEMBL3487334 | 0.81 | L3MBTL1 (0.46) | SIGMAR1FFAR1EPHX2MMP1MMP13 | |
| SCHEMBL3487365 | 0.81 | SIGMAR1 (0.47) | SIGMAR1FFAR1KDM4EMMP1MMP13 | |
| SCHEMBL2820441 | 0.81 | SIGMAR1 (0.47) | SIGMAR1FFAR1KDM4EMMP1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389511-B2 | Bicyclic heterocyclic derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-03-05 | — | — | US | disclosed |
| EP-2243779-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-10-27 | — | — | EP | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056497-A1 | AMIDE DERIVATIVE | REN, AGTR1, AGTR2 | SIGMAR1 570/4885FFAR1 2159/4885KDM4E 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.